Tharimmune

Canton Strategic Holdings, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 12 full-time employees. The company went IPO on 2022-01-12. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The firm also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.